Quantitative Investment Management, LLC Nektar Therapeutics Transaction History

Quantitative Investment Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$16.52 - $20.4 $657,958 - $812,491	-39,828 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$16.56 - $25.46 $659,551 - $1.01 Million	39,828 New	39,828 $796,000
Q3 2020 Nov 13, 2020	SELL	$16.59 - $24.79 $1.13 Million - $1.69 Million	-68,345 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$16.86 - $23.44 $958,002 - $1.33 Million	56,821 Added 493.07%	68,345 $1.58 Million
Q1 2020 May 15, 2020	BUY	$14.47 - $27.96 $166,752 - $322,211	11,524 New	11,524 $205,000
Q2 2019 Aug 14, 2019	SELL	$31.0 - $36.3 $892,800 - $1.05 Million	-28,800 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$31.58 - $46.35 $113,688 - $166,860	-3,600 Reduced 11.11%	28,800 $967,000
Q4 2018 Feb 12, 2019	BUY	$30.43 - $56.65 $410,805 - $764,775	13,500 Added 71.43%	32,400 $1.06 Million
Q3 2018 Nov 14, 2018	SELL	$46.46 - $68.49 $8.93 Million - $13.2 Million	-192,300 Reduced 91.05%	18,900 $1.15 Million
Q2 2018 Aug 10, 2018	BUY	$46.25 - $104.45 $9.77 Million - $22.1 Million	211,200 New	211,200 $10.3 Million

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $127M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Quantitative Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Quantitative Investment Management, LLC with notifications on news.